Leadership Overview
Versiti has 9 executives leading key functions including strategy, operations, finance, information technology, and human resources.
Driven by innovation, Versiti is dedicated to improving patient health and enabling the success of healthcare partners nationwide through advanced solutions in transfusion medicine, transplantation, and blood-related diseases.
Driven by innovation, Versiti is dedicated to improving patient health and enabling the success of healthcare partners nationwide through advanced solutions in transfusion medicine, transplantation, and blood-related diseases.
Leadership Roles at Versiti
Jacqueline Fredrick - Chief Executive Officer
Jacqueline Fredrick, the Chief Executive Officer at Versiti, directs the overarching strategy and vision for the organization. Fredrick's leadership focuses on advancing Versiti's mission to improve patient health and support healthcare partners across the nation. This involves guiding the company's innovative solutions in transfusion medicine, transplantation, and blood-related diseases. Fredrick ensures that the collective efforts across Versiti yield improved patient outcomes, expanded access to care, and significant cost efficiencies for healthcare systems. The strategic direction set by Jacqueline Fredrick is critical to maintaining Versiti's position as a national leader in blood health innovation and driving forward its commitment to value-added services.
Dennis Mestrich - President & Chief Executive Officer
Dennis Mestrich, the President & Chief Executive Officer at Versiti, spearheads the organization's strategic initiatives and operational execution. Mestrich's role involves driving the company's mission to enhance patient health and foster success for healthcare partners nationwide. This leadership encompasses the development and delivery of innovative solutions within transfusion medicine, transplantation, and blood-related diseases. Dennis Mestrich ensures that Versiti's operations contribute to improved patient outcomes, broader access to critical care, and greater cost-effectiveness for healthcare systems. The executive leadership provided by Dennis Mestrich is fundamental to Versiti's ongoing growth and its impact on blood health innovation.
Christopher Miskel - President & Chief Executive Officer
Christopher Miskel, the President & Chief Executive Officer at Versiti, guides the strategic direction and operational framework of the organization. Miskel's leadership is central to Versiti's commitment to improving patient health and empowering healthcare partners across the country. This involves overseeing the delivery of advanced, value-added solutions in transfusion medicine, transplantation, and blood-related diseases. Christopher Miskel ensures that Versiti's integrated approach leads to enhanced patient outcomes, wider access to essential healthcare services, and improved financial performance for healthcare systems. The executive oversight from Christopher Miskel is vital for Versiti's continued leadership in blood health innovation.
Byron Buhner - President & Chief Executive Officer
Byron Buhner, the President & Chief Executive Officer at Versiti, directs the strategic vision and operational execution for the organization. Buhner's leadership is focused on advancing Versiti's core mission: improving patient health and ensuring the success of its healthcare partners nationwide. This involves championing innovative solutions in transfusion medicine, transplantation, and blood-related diseases. Byron Buhner ensures that Versiti's collective efforts translate into tangible benefits, including better patient outcomes, expanded access to care, and significant cost efficiencies for healthcare systems. The strategic guidance provided by Byron Buhner is essential for Versiti's sustained impact and leadership in blood health innovation.
Terri Ainsworth - Chief Financial Officer
Terri Ainsworth, the Chief Financial Officer at Versiti, manages the organization's financial operations and strategic fiscal planning. Ainsworth's responsibilities include ensuring financial stability and driving economic strategies that support Versiti's mission to improve patient health and empower healthcare partners. This involves overseeing budgeting, financial reporting, and investment strategies for innovative solutions in transfusion medicine, transplantation, and blood-related diseases. Terri Ainsworth ensures that financial resources are allocated effectively to achieve improved patient outcomes, expand access to care, and maintain cost efficiencies for healthcare systems nationwide. The financial acumen of Terri Ainsworth is crucial for Versiti's sustained growth and leadership.
Anthony Watkins - Executive Vice President & Chief Financial Officer
Anthony Watkins, the Executive Vice President & Chief Financial Officer at Versiti, directs the company's financial strategy and fiscal management. Watkins' leadership ensures robust financial planning and resource allocation to support Versiti's mission of improving patient health and enabling healthcare partner success. This involves overseeing all financial operations, including budgeting, forecasting, and investment in innovative solutions for transfusion medicine, transplantation, and blood-related diseases. Anthony Watkins drives financial discipline and strategic investments to enhance patient outcomes, expand access to care, and maintain cost efficiencies for healthcare systems across the nation. The financial oversight provided by Anthony Watkins is critical to Versiti's operational integrity and its leadership in blood health innovation.
Brian Bautista - Executive Vice President & Chief Operating Officer
Brian Bautista, the Executive Vice President & Chief Operating Officer at Versiti, oversees the day-to-day operations and execution of strategic initiatives across the organization. Bautista's role is critical in ensuring the efficient delivery of Versiti's value-added solutions in transfusion medicine, transplantation, and blood-related diseases. This involves optimizing operational processes to improve patient outcomes, expand access to care, and achieve cost efficiencies for healthcare systems nationwide. Brian Bautista drives operational excellence, ensuring that Versiti's collective efforts align with its mission to improve patient health and support its healthcare partners. The operational leadership of Brian Bautista is fundamental to Versiti's national impact and its commitment to blood health innovation.
Rodeina Davis - Chief Information Officer
Rodeina Davis, the Chief Information Officer at Versiti, architects the organization's technology strategy and digital infrastructure. Davis oversees the implementation and management of information systems that support Versiti's mission to improve patient health and enable healthcare partner success. This includes driving innovation in data management and technology solutions critical for transfusion medicine, transplantation, and blood-related diseases. Rodeina Davis ensures that technology enhances operational efficiency, supports advanced research, and contributes to improved patient outcomes and cost efficiencies nationwide. The strategic technology leadership from Rodeina Davis is pivotal for Versiti's continued advancement in blood health innovation.
Lynne Briggs - Vice President & Chief Information Officer
Lynne Briggs, the Vice President & Chief Information Officer at Versiti, directs the company's information technology infrastructure and digital transformation initiatives. Briggs' leadership ensures that technology systems effectively support Versiti's mission to improve patient health and enable the success of its healthcare partners. This involves overseeing the development and deployment of innovative technological solutions for transfusion medicine, transplantation, and blood-related diseases. Lynne Briggs focuses on enhancing data security, optimizing system performance, and leveraging technology to drive improved patient outcomes and operational efficiencies across the nation. The strategic IT vision of Lynne Briggs is integral to Versiti's ongoing advancements in blood health innovation.
James Weidner - Executive Vice President & Chief Human Resources Officer
James Weidner, the Executive Vice President & Chief Human Resources Officer at Versiti, leads the strategic development and execution of human capital initiatives. Weidner's focus is on cultivating a high-performing workforce that supports Versiti's mission to improve patient health and empower its healthcare partners. This involves overseeing talent acquisition, employee development, and organizational culture programs that align with the company's innovative work in transfusion medicine, transplantation, and blood-related diseases. James Weidner ensures that Versiti attracts, retains, and develops top talent, fostering an environment that drives improved patient outcomes and operational efficiencies nationwide. The HR leadership of James Weidner is vital for Versiti's sustained success and its commitment to blood health innovation.
Explore Leadership Teams in Blood & Organ Banks
信达生物制药 specializes in the research, development, and production of innovative biopharmaceuticals. The company focuses on providing advanced therapies for various diseases, particularly in oncology and autoimmune disorders. Its intended clients include healthcare providers, hospitals, and patients seeking effective treatment options. With a commitment to quality and innovation, 信达生物制药 aims to improve patient outcomes through its cutting-edge products.
Company Leadership
HX
Serum Institute of India Pvt. Ltd., founded in 1966 and headquartered in Pune, India, is a manufacturer of immunobiological drugs including vaccines in India.
Company Leadership PD
MC
Bloodworks Northwest, founded in 1944 and headquartered in Seattle, Washington is a non- profit blood donation organization that collects, tests and distributes blood to hospitals throughout the Northwest.
Company Leadership BF
AS
RG
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership MP
HA
KL
SL
Frequently Asked Questions Regarding Versiti Top Executives and Leadership Team
Unlock more people and company data
